Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA:603456)
China flag China · Delayed Price · Currency is CNY
16.16
-0.48 (-2.88%)
Nov 6, 2026, 3:00 PM CST

SHA:603456 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
5,1925,4165,0865,4065,1813,823
Other Revenue
92.6892.6874.24117.58264.29240.52
5,2855,5095,1615,5235,4454,063
Revenue Growth
-1.33%6.74%-6.57%1.44%34.01%53.49%
Cost of Revenue
3,5603,6463,5713,5243,6232,746
Gross Profit
1,7251,8631,5901,9991,8221,317
Selling, General & Admin
510.03497.92513.31524.15480.09383.42
Research & Development
261.35256.99314.91330.83287.38173.36
Other Operating Expenses
44.1651.0129.4721.9734.6726.52
Operating Expenses
830.2791.11874.34896.32796.43590.87
Operating Income
894.321,072715.311,1031,026725.97
Interest Expense
-7.75-10.12-19.38-21.73-22.38-24.87
Interest & Investment Income
46.9344.8786.0691.8215.2768.74
Currency Exchange Gain (Loss)
-12.91-12.9112.529.0297.03-18.36
Other Non Operating Income (Expenses)
-28.3-2.02-1.33-4.27-2.02-2.29
EBT Excluding Unusual Items
892.291,091793.181,1781,114749.19
Impairment of Goodwill
-76-76-21.511.32-0.87-10.86
Gain (Loss) on Sale of Investments
2.94--8.13-19.36-35.22-1.39
Gain (Loss) on Sale of Assets
-7.23-6.38-13.54-4.03-8.85-16.57
Asset Writedown
-51.44-98.09-39.11-0.13--5.54
Other Unusual Items
6.988.5319.7225.2635.0329.92
Pretax Income
767.53919.45730.61,1811,104744.74
Income Tax Expense
180.7190.91123.53149.27182.85110.59
Earnings From Continuing Operations
586.83728.54607.071,031920.97634.15
Minority Interest in Earnings
12.371.53-0.971.880.2-0.25
Net Income
599.2730.07606.11,033921.17633.9
Net Income to Common
599.2730.07606.11,033921.17633.9
Net Income Growth
-17.11%20.46%-41.34%12.17%45.32%66.56%
Shares Outstanding (Basic)
893890891891830823
Shares Outstanding (Diluted)
893890891891830834
Shares Change
1.16%-0.11%0.07%7.33%-0.50%3.00%
EPS (Basic)
0.670.820.681.161.110.77
EPS (Diluted)
0.670.820.681.161.110.76
EPS Growth
-18.06%20.59%-41.38%4.50%46.05%61.70%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
815.71,164102.69430.88511.9997.64
Free Cash Flow Per Share
0.911.310.120.480.620.12
Dividend Per Share
0.2000.3000.3000.5000.4000.250
Dividend Growth
-60.00%0%-40.00%25.00%60.00%25.00%
Gross Margin
32.63%33.81%30.80%36.19%33.47%32.41%
Operating Margin
16.92%19.45%13.86%19.96%18.84%17.87%
Profit Margin
11.34%13.25%11.74%18.71%16.92%15.60%
Free Cash Flow Margin
15.43%21.13%1.99%7.80%9.40%2.40%
EBITDA
1,3071,4801,1181,4791,3691,017
EBITDA Margin
24.73%26.87%21.67%26.77%25.13%25.04%
D&A For EBITDA
412.41408.43403.12376.06342.67291.37
EBIT
894.321,072715.311,1031,026725.97
EBIT Margin
16.92%19.45%13.86%19.96%18.84%17.87%
Effective Tax Rate
23.54%20.76%16.91%12.64%16.56%14.85%
Revenue as Reported
5,2855,5095,1615,5235,4454,063